Table 2a.

Relationship Between Immune Cell Markers and Clinicopathological Characteristics

Characteristics	CD4			CD8			FOXP3
	Negative	Positive	P	Negative	Positive	P	Negative	Positive	P
	n (%)	n (%)		n (%)	n (%)		n (%)	n (%)
Age
≤57	36 (45)	52 (62.7)	.0238	39 (45.9)	50 (58.1)	.1087	42 (56)	46 (49)	.3611
>57	44 (55)	31 (37.3)		46 (51.1)	36 (41.9)		33 (44)	48 (51)
Histological type
IDC	70 (87.5)	69 (83.1)	.3163	71 (83.5)	72 (83.7)	.9273	63 (82.9)	78 (83.9)	.6803
ILC	7 (8.75)	6 (7.2)		9 (10.6)	8 (9.3)		9 (11.8)	8 (8.6)
Other	3 (3.75)	8 (9.6)		5 (5.9)	6 (7)		4 (5.3)	7 (7.5)
Tumor size (cm)
≤2 cm	44 (55.7)	56 (68.3)	.0995	56 (65.9)	53 (62.4)	.6314	52 (69.3)	55 (59.1)	.172
>2 cm	35 (44.3)	26 (31.7)		29 (34.1)	32 (37.6)		23 (30.7)	38 (40.9)
Lymph node status
Negative	52 (65.8)	47 (57.3)	.2675	56 (65.9)	48 (57.1)	.243	42 (56.8)	60 (64.5)	.307
Positive	27 (34.2)	35 (42.7)		29 (34.1)	36 (42.9)		32 (43.2)	33 (35.5)
Histological grade
G1	5 (6.3)	6 (7.5)	.1212	5 (6)	9 (10.7)	.033	8 (10.7)	6 (6.7)	.6756
G2	52 (65.8)	40 (50)		57 (68.7)	41 (48.8)		44 (58.7)	51 (56.7)
G3	22 (27.9)	34 (42.5)		21 (25.3)	34 (40.5)		23 (30.6)	33 (36.6)
Receptor status
ER-negative (≤10%)	10 (12.5)	20 (24.7)	.047	13 (15.3)	17 (20.2)	.4003	12 (16.2)	18 (19.4)	.5997
ER-positive (>10%)	70 (87.5)	61 (75.3)		72 (84.7)	67 (79.8)		62 (83.8)	75 (80.6)
PgR-negative (≤ 10%)	23 (28.8)	33 (40.7)	.1102	28 (32.9)	34 (40.5)	.3095	21 (28.4)	41 (44.1)	.0369
PgR-positive (> 10%)	57 (71.2)	48 (59.3)		57 (67.1)	50 (59.5)		53 (71.6)	52 (55.9)
MIB1
Negative (≤20%)	62 (77.5)	43 (53.1)	.0011	64 (75.3)	51 (60.7)	.0421	54 (73)	61 (65.6)	.3062
Positive (>20%)	18 (22.5)	38 (46.9)		21 (24.7)	33 (39.3)		20 (27)	32 (34.4)
HER2/neu
Negative (0,1+)	73 (91.2)	61 (76.3)	.0101	75 (88.2)	67 (80.7)	.1783	64 (86.5)	75 (81.5)	.3889
Positive (3+)	7 (8.8)	19 (23.7)		10 (11.8)	16 (19.3)		10 (13.5)	17 (18.5)